(II-1.A.4d) 30-year-old patient with arterial pulmonary hypertension and ascending aortic aneurysm Natasza Herman, Paweł Prochownik, Urszula Gancarczyk, Monika Komar, Bartosz Sobień, Piotr Podolec
EXPERTISE 1 “Development of the European Network in Orphan Cardiovascular Diseases” “Rozszerzenie Europejskiej Sieci Współpracy ds. Sierocych Chorób Kardiologicznych”
(II-2A.2) 68 y/o female with increasing dysponoe: corrected mitral valve disease with right pulmonary artery stenosis Prof. E. Ereminienė, Assoc. Prof. G. Jaruševičius assist. B. Gumauskienė, Res. A. Adukauskaitė, Res. A. Andreikėnaitė
BRIEF COMMENTS EXPERT: Assoc. Prof. Jacek Kołcz, MD, PhD, pediatric cardiac surgeon Affiliation: Department of Pediatric Cardiac Surgery, Jagiellonian University Medical College, Krakow, Poland COMMENT Thrombogenic complication seems more probable than primary vessel pathology. From a surgical point of view reconstruction of the artery is impossible. Conservative treatment appears to be the best option. EXPERT: Prof. Piotr Podolec MD, PhD, cardiologist Affiliation: Department of Cardiac and Vascular Diseases, John Paul II Hospital, Krakow, Poland COMMENT Specific treatment of pulmonary …
(II-1A.1) 51-year old woman with idiopatic pulmonary arterial hypertension, atrial flutter and thrombus in right atrium Barbara Widlińska, Marcin Waligóra, Anna Tyrka, Monika Komar, Agnieszka Sarnecka, Mateusz Brózda, Paweł Prochownik, Urszula Gancarczyk, Natasza Herman, Piotr Podolec
EXPERTISE 1 “Development of the European Network in Orphan Cardiovascular Diseases” “Rozszerzenie Europejskiej Sieci Współpracy ds. Sierocych Chorób Kardiologicznych”
(IV-1C.3/II-2A.1) 41-year old patient with arterial pulmonary hypertension and unilateral pulmonary artery absence Blaszczak Piotr MD PhD, Grzywna Ryszard MD PhD, Gorczyca Daria MD, Siudak Łukasz MD
EXPERTISE 1 “Development of the European Network in Orphan Cardiovascular Diseases” “Rozszerzenie Europejskiej Sieci Współpracy ds. Sierocych Chorób Kardiologicznych”
Posted in 1. Abnormalities of the position and connection of the heart and vessels, 1. Atresia of the pulmonary artery, 2. Inborn anomalies of the pulmonary vessels, 3. Great arteries, A. Anomalous morphology, C. Veins and arteries, Case presentations, II. Rare diseases of pulmonary circulation, IV. Rare congenital cardiovascular diseases
Leave a comment
(II-1B.1) 59-year-old woman with non-ischemic dilated cardiomyopathy and secondary pulmonary hypertension reactive to sildenafil Paweł Iwaszczuk, Monika Smaś-Suska, Marta Szuksztul, Magdalena Kaźnica-Wiatr, Lidia Tomkiewicz-Pająk, Piotr Musiałek, Maria Olszowska, Piotr Podolec
“Development of the European Network in Orphan Cardiovascular Diseases” “Rozszerzenie Europejskiej Sieci Współpracy ds. Sierocych Chorób Kardiologicznych”
(II-1A.4d) 71-year-old patient with patent ductus arteriosus P. Prochownik, A. Sarnecka MD, G. Kopeć MD, PhD, M. Komar MD, PhD, Prof. P. Podolec MD, PhD
BRIEF COMMENTS EXPERT: Krzysztof Szymoński, MD Affiliation: Department of Cardiovascular Surgery and Transplantology, John Paul II Hospital, Krakow, Poland COMMENT Due to current ESC guidelines the patient qualifies for PDA closure. Tricuspid valvuloplasty may also be considered. EXPERT: Grzegorz Kopeć, MD, PhD Affiliation: Department of Cardiac and Vascular Diseases, John Paul II Hospital, Krakow COMMENT Because there is no possibility of pulmonary hypertension targeted treatment the patient qualifies for PDA closure. Coexisting tricuspid regurgitation seems to be secondary to …
(II-1B1) Spectacular improvement in a 50 year old urgent heart transplant candidate after 3-month phosphodiesterase type 5 inhibitor (sildenafil) treatment Marta Szuksztul, Paweł Rubiś MD, PhD, Monika Dzieciuch-Rojek, Sylwia Wiśniowska-Śmiałek MD, Dawid Kudliński, Agata Leśniak-Sobelga MD, PhD, Magdalena Kostkiewicz MD, PhD, Prof. Piotr Podolec MD, PhD
BRIEF COMMENTS EXPERT: Prof. Roland Hetzer, MD, PhD Affiliation: German Heart Instiute, Berlin, Germany COMMENT The patient responded well to the administered treatment (improvement of LVEF and gradual reduction of pulmonary hypertension) although the LV size didn’t change. Due to severe mitral regurgitation mitral valve repair should be considered, cardiosurgical consultation is required. The patient may need heart transplantation in the future. Furthermore CRT may be an option if such a procedure is technically feasible. EXPERT: Prof. Egle Ereminiene, …
(II-1A.1) Idiopathic pulmonary artery hypertension
BRIEF COMMENTS EXPERT: Prof. Henryk Siniawski MD, PhD, cardiac surgeon Affiliation: Deutsches Herzzentrum, Berlin, Germany COMMENT What was the initial function of the heart – in case of iPAH usually only lungs transplantation is performed, RV function often normalizes after lung-transplantation. Perhaps solitary lung transplantation would safe patient’s coronary arteries. EXPERT: Prof. Egle Ereminiene MD, PhD Affiliation: Hospital of Lithuanian University of Health Sciences, Kaunas COMMENT Poor RV function was the main reason of complex lungs and heart transplantation. …
(II-1A.5) 41-year-old patient with chronic thromboembolic pulmonary hypertension Marcin Waligóra MD, Agnieszka Sarnecka MD, Grzegorz Kopeć MD, PhD, Prof. Piotr Podolec MD, PhD
https://i1.wp.com/www.crcd.eu/wp-content/uploads/2013/07/image11.png?fit=190%2C169
Background Acute pulmonary embolism is rarely complicated by development of pulmonary hypertension (PH) with estimated incidence rate of 0,5-2%. It is almost impossible to determine the overall prevalence of chronic thromboembolic pulmonary hypertension (CTEPH) since not all of these patients have a history of acute pulmonary embolism. For patients after acute pulmonary embolism, diagnosis can be made after 3 months of effective anticoagulation, and remaining signs of PH. Final diagnosis can be made after confirming pre-capillary PH during right heart …
(II-1A.4b) Pulmonary arterial hypertension associated with HIV and HCV infection Michał Furdal, Ewa Mroczek, Jakub Stępniewski
Background Pulmonary arterial hypertension (PAH) is a rare, but one of the most frequent complications of HIV infection. 3- year survival of patients with HIV related PAH (HIV-PAH) remaining in functional class III or IV by WHO (FC WHO) reaches approximately 20-30%. It is believed that highly active antiretroviral therapy (cART) or dysfunction of immune system and CD4 lymphocytes has less likely influence on the occurrence or the course of PAH. There is still limited data on the utilization of …